Schooley Elizabeth K, McGee Turner Joseph B, Jiji Renee D, Spinka Christine M, Reinero Carol R
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA.
Am J Vet Res. 2007 Nov;68(11):1265-71. doi: 10.2460/ajvr.68.11.1265.
To determine whether oral administration of cyproheptadine or cetirizine blocks the action of serotonin and histamine, respectively, and results in diminished eosinophilic airway inflammation in cats with experimentally induced asthma.
9 cats in which asthma was experimentally induced through exposure to Bermuda grass allergen (BGA) during a 3-month period.
Cats were randomized to receive monotherapy with each of 3 treatments for 1 week: placebo (flour in a gelatin capsule, PO, q 12 h), cyproheptadine (8 mg, PO, q 12 h), or cetirizine (5 mg, PO, q 12 h). A 1-week washout period was allowed to elapse between treatments. Prior to and following each 1-week treatment period, blood and bronchoalveolar lavage fluid (BALF) samples were collected. The percentage of eosinophils in BALF was evaluated to determine treatment efficacy. Serum and BALF BGA-specific immunoglobulin contents and plasma and BALF histamine concentrations were determined via ELISAs. Plasma and BALF serotonin concentrations were measured by use of a fluorometric method.
The mean +/- SD percentage of eosinophils in BALF did not differ significantly among treatment groups (placebo, 40 +/- 22%; cyproheptadine, 27 +/- 16%; and cetirizine, 31 +/- 20%). Among the treatment groups, BGA-specific immunoglobulin content and histamine and serotonin concentrations were not significantly different.
In cats with experimentally induced asthma, cyproheptadine and cetirizine were not effective in decreasing airway eosinophilic inflammation or in altering several other measured immunologic variables. Neither cyproheptadine nor cetirizine can be advocated as monotherapy for cats with allergen-induced asthma.
确定口服赛庚啶或西替利嗪是否分别阻断血清素和组胺的作用,并减少实验性诱发哮喘猫的嗜酸性气道炎症。
9只猫,在3个月期间通过暴露于百慕大草过敏原(BGA)实验性诱发哮喘。
将猫随机分为3种治疗方法中的每种单药治疗1周:安慰剂(明胶胶囊中的面粉,口服,每12小时一次)、赛庚啶(8毫克,口服,每12小时一次)或西替利嗪(5毫克,口服,每12小时一次)。治疗之间允许有1周的洗脱期。在每个1周治疗期之前和之后,采集血液和支气管肺泡灌洗液(BALF)样本。评估BALF中嗜酸性粒细胞的百分比以确定治疗效果。通过酶联免疫吸附测定法测定血清和BALF中BGA特异性免疫球蛋白含量以及血浆和BALF中组胺浓度。使用荧光法测量血浆和BALF中血清素浓度。
治疗组之间BALF中嗜酸性粒细胞的平均±标准差百分比无显著差异(安慰剂组为40±22%;赛庚啶组为27±16%;西替利嗪组为31±20%)。在治疗组中,BGA特异性免疫球蛋白含量以及组胺和血清素浓度无显著差异。
在实验性诱发哮喘的猫中,赛庚啶和西替利嗪在减少气道嗜酸性炎症或改变其他几个测量的免疫变量方面无效。赛庚啶和西替利嗪均不能作为过敏原诱发哮喘猫的单一疗法推荐。